Tanvex BioPharma Inc Working Capital to Net Assets Ratio
Tanvex BioPharma Inc working capital to net assets ratio. Tanvex BioPharma Inc (6541) has a Working Capital to Net Assets ratio of 5.1% as of March 2026. Working capital of NT$276.13 Million (current assets of NT$1.10 Billion minus current liabilities of NT$827.46 Million) is measured against net assets of NT$5.36 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Tanvex BioPharma Inc (6541) tangible net worth to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Tanvex BioPharma Inc (2013–2025)
Working capital to net assets ratio of Tanvex BioPharma Inc from 2013 to 2025. This chart shows how Tanvex BioPharma Inc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 5.1%, reflecting working capital of NT$276.13 Million against net assets of NT$5.36 Billion TWD. See 6541 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Tanvex BioPharma Inc Working Capital to Net Assets Ratio by Year (2013–2025)
Tanvex BioPharma Inc working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Tanvex BioPharma Inc from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Tanvex BioPharma Inc's balance sheet.
| Year | WC/NA Ratio | Working Capital (TWD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 12.3% | NT$697.52 Million | NT$5.69 Billion | NT$1.50 Billion | NT$799.66 Million | ▼ -24.4 pp |
| 2024 | 36.7% | NT$327.48 Million | NT$893.31 Million | NT$675.62 Million | NT$348.14 Million | ▲ +7.4 pp |
| 2023 | 29.3% | NT$240.48 Million | NT$821.11 Million | NT$604.21 Million | NT$363.73 Million | ▼ -23.9 pp |
| 2022 | 53.2% | NT$740.43 Million | NT$1.39 Billion | NT$1.04 Billion | NT$303.29 Million | ▼ -23.8 pp |
| 2021 | 77.1% | NT$2.15 Billion | NT$2.79 Billion | NT$2.40 Billion | NT$248.51 Million | ▲ +4.2 pp |
| 2020 | 72.9% | NT$1.91 Billion | NT$2.62 Billion | NT$2.26 Billion | NT$353.10 Million | ▼ -4.1 pp |
| 2019 | 77.0% | NT$2.33 Billion | NT$3.03 Billion | NT$2.60 Billion | NT$270.45 Million | ▼ -5.7 pp |
| 2018 | 82.7% | NT$3.49 Billion | NT$4.21 Billion | NT$3.70 Billion | NT$209.46 Million | ▲ +2.4 pp |
| 2017 | 80.3% | NT$3.01 Billion | NT$3.75 Billion | NT$3.18 Billion | NT$164.70 Million | ▲ +4.2 pp |
| 2016 | 76.1% | NT$2.72 Billion | NT$3.57 Billion | NT$2.95 Billion | NT$233.15 Million | ▲ +29.3 pp |
| 2015 | 46.8% | NT$678.07 Million | NT$1.45 Billion | NT$780.47 Million | NT$102.40 Million | ▲ +17.4 pp |
| 2014 | 29.4% | NT$173.55 Million | NT$589.64 Million | NT$218.43 Million | NT$44.88 Million | ▼ -0.3 pp |
| 2013 | 29.8% | NT$120.18 Million | NT$403.64 Million | NT$182.77 Million | NT$62.59 Million | — |